Literature DB >> 19033646

Harnessing endogenous miR-181a to segregate transgenic antigen receptor expression in developing versus post-thymic T cells in murine hematopoietic chimeras.

Eirini P Papapetrou1, Damian Kovalovsky, Laurent Beloeil, Derek Sant'angelo, Michel Sadelain.   

Abstract

MicroRNAs (miRNAs) are small, noncoding RNAs that regulate gene expression by targeting complementary sequences, referred to as miRNA recognition elements (MREs), typically located in the 3' untranslated region of mRNAs. miR-181a is highly expressed in developing thymocytes and markedly downregulated in post-thymic T cells. We investigated whether endogenous miR-181a can be harnessed to segregate expression of chimeric antigen receptors (CARs) and TCRs between developing and mature T cells. Lentiviral-encoded antigen receptors were tagged with a miR-181a-specific MRE and transduced into mouse BM cells that were used to generate hematopoietic chimeras. Expression of a CAR specific for human CD19 (hCD19) was selectively suppressed in late double-negative and double-positive thymocytes, coinciding with the peak in endogenous miR-181a expression. Receptor expression was fully restored in post-thymic resting and activated T cells, affording protection against a subsequent challenge with hCD19+ tumors. Hematopoietic mouse chimeras engrafted with a conalbumin-specific TCR prone to thymic clonal deletion acquired peptide-specific T cell responsiveness only when the vector-encoded TCR transcript was similarly engineered to be subject to regulation by miR-181a. These results demonstrate the potential of miRNA-regulated transgene expression in stem cell-based therapies, including cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19033646      PMCID: PMC2613472          DOI: 10.1172/JCI37216

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  52 in total

Review 1.  Immunity against cancer: lessons learned from melanoma.

Authors:  A N Houghton; J S Gold; N E Blachere
Journal:  Curr Opin Immunol       Date:  2001-04       Impact factor: 7.486

2.  Identification of novel genes coding for small expressed RNAs.

Authors:  M Lagos-Quintana; R Rauhut; W Lendeckel; T Tuschl
Journal:  Science       Date:  2001-10-26       Impact factor: 47.728

3.  The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation.

Authors:  P H Olsen; V Ambros
Journal:  Dev Biol       Date:  1999-12-15       Impact factor: 3.582

4.  Identification of tissue-specific microRNAs from mouse.

Authors:  Mariana Lagos-Quintana; Reinhard Rauhut; Abdullah Yalcin; Jutta Meyer; Winfried Lendeckel; Thomas Tuschl
Journal:  Curr Biol       Date:  2002-04-30       Impact factor: 10.834

5.  Inactivation of Notch 1 in immature thymocytes does not perturb CD4 or CD8T cell development.

Authors:  A Wolfer; T Bakker; A Wilson; M Nicolas; V Ioannidis; D R Littman; P P Lee; C B Wilson; W Held; H R MacDonald; F Radtke
Journal:  Nat Immunol       Date:  2001-03       Impact factor: 25.606

6.  Negative selection of thymocytes expressing the D10 TCR.

Authors:  Derek B Sant'Angelo; Charles A Janeway
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-14       Impact factor: 11.205

7.  An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans.

Authors:  N C Lau; L P Lim; E G Weinstein; D P Bartel
Journal:  Science       Date:  2001-10-26       Impact factor: 47.728

8.  An extensive class of small RNAs in Caenorhabditis elegans.

Authors:  R C Lee; V Ambros
Journal:  Science       Date:  2001-10-26       Impact factor: 47.728

Review 9.  Development of gene therapy for blood disorders.

Authors:  Arthur W Nienhuis
Journal:  Blood       Date:  2008-05-01       Impact factor: 22.113

10.  Dynamic tuning of T cell reactivity by self-peptide-major histocompatibility complex ligands.

Authors:  P Wong; G M Barton; K A Forbush; A Y Rudensky
Journal:  J Exp Med       Date:  2001-05-21       Impact factor: 14.307

View more
  30 in total

Review 1.  Recent advances in lentiviral vector development and applications.

Authors:  Janka Mátrai; Marinee K L Chuah; Thierry VandenDriessche
Journal:  Mol Ther       Date:  2010-01-19       Impact factor: 11.454

Review 2.  Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications.

Authors:  Brian D Brown; Luigi Naldini
Journal:  Nat Rev Genet       Date:  2009-08       Impact factor: 53.242

Review 3.  Improving miRNA Delivery by Optimizing miRNA Expression Cassettes in Diverse Virus Vectors.

Authors:  Elena Herrera-Carrillo; Ying Poi Liu; Ben Berkhout
Journal:  Hum Gene Ther Methods       Date:  2017-08       Impact factor: 2.396

Review 4.  RNA viruses and the host microRNA machinery.

Authors:  Benjamin R tenOever
Journal:  Nat Rev Microbiol       Date:  2013-03       Impact factor: 60.633

Review 5.  Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.

Authors:  Bipulendu Jena; Gianpietro Dotti; Laurence J N Cooper
Journal:  Blood       Date:  2010-05-03       Impact factor: 22.113

Review 6.  Hematopoietic stem cells for cancer immunotherapy.

Authors:  Eric Gschweng; Satiro De Oliveira; Donald B Kohn
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 7.  Retroviral vector interactions with hematopoietic cells.

Authors:  Elizabeth M Everson; Grant D Trobridge
Journal:  Curr Opin Virol       Date:  2016-08-10       Impact factor: 7.090

8.  microRNA as a new immune-regulatory agent in breast milk.

Authors:  Nobuyoshi Kosaka; Hirohisa Izumi; Kazunori Sekine; Takahiro Ochiya
Journal:  Silence       Date:  2010-03-01

9.  Ectopic T cell receptor-α locus control region activity in B cells is suppressed by direct linkage to two flanking genes at once.

Authors:  Stefan Knirr; Janette Gomos-Klein; Blanca E Andino; Faith Harrow; Karl F Erhard; Damian Kovalovsky; Derek B Sant'Angelo; Benjamin D Ortiz
Journal:  PLoS One       Date:  2010-11-22       Impact factor: 3.240

Review 10.  Myeloprotection by cytidine deaminase gene transfer in antileukemic therapy.

Authors:  Nico Lachmann; Sebastian Brennig; Ruhi Phaltane; Michael Flasshove; Dagmar Dilloo; Thomas Moritz
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.